RxDoctor Payments Data

Lauren Gendrich

Primary Care · Birmingham, ALNPI 1962172189

Payments from drug & device makers

$739in general payments, 2019–2025

Across 22 payments — averaging $33.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$215
  • Boston Scientific$174
  • Johnson & Johnson$148
  • Janssen Scientific Affairs, LLC$37
  • Amgen$27
  • Edwards Lifesciences$25
  • plus $114 from 6 others

What the payments were for

  • Food & beverage$739100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$739 in reported general payments places this provider in the 50th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$9,283
Medicare patients
98
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan62$68,243
EliquisApixaban57$58,888
JardianceEmpagliflozin31$40,002
Repatha SureclickEvolocumab31$23,536
FarxigaDapagliflozin Propanediol14$11,989
Repatha SyringeEvolocumab11$5,780
Ranolazine ErRanolazine57$5,270
Metoprolol Succinate132$2,245
Atorvastatin Calcium125$1,912
Isosorbide Mononitrate ErIsosorbide Mononitrate92$1,258
Carvedilol72$1,010
Isosorbide Dinitrate11$994
Rosuvastatin Calcium33$894
Amlodipine Besylate87$750
Ezetimibe27$706

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$215$68,24362 claims
PfizerEliquis$18$58,88857 claims
AstraZenecaFarxiga$14$11,98914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 159 primary care providers in Alabama.

Other primary care in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →